Apixaban also called as Eliquis is an anti-clotting drug which acts by thinning the blood cells. It is also allowed to be used among the patients suffering from recurrence of Deep vein thrombosis and pulmonary embolism problems due to relapse in treatment.
On August 19, FDA announced their approval decision. It has to be noted that Eliquis was already approved as an anti-clotting drug to lower the risks related to atrial fibrillation, stroke.
DVT and PE patients who had hip-replacement or knee-replacement surgery were frequently prescribed the drug Eliquis. It is a factor Xa inhibitor acting as an antithrombin drug.
Earlier, in clinical trials, it was reported that Apixaban has shown better results compared to the widely used anticoagulant drug, the warfarin for preventing strokes.
The European Commission has already granted an extension for the use of Apixaban drug in countries which comes under the European Medicines Agency.